## **DEPARTMENT OF HEALTH SERVICES**

Division of Medicaid Services F-11083 (04/2017)

## STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

## FORWARDHEALTH PRIOR AUTHORIZATION / BRAND MEDICALLY NECESSARY ATTACHMENT (PA/BMNA)

**Instructions:** Type or print clearly. Before completing this form, read the Prior Authorization/Brand Medically Necessary Attachment (PA/BMNA) Completion Instructions, F-11083A. Providers may refer to the Forms page of the ForwardHealth Portal at <a href="https://www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage">www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage</a> for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Brand Medically Necessary Attachment (PA/BMNA) form signed by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION				
Name – Member (Last, First, Middle Initial)				
2. Member Identification Number	3. Date of Birth – Member			
SECTION II – PRESCRIPTION INFORMATION				
4. Drug Name	5. Drug Strength			
6. Date Prescription Written	7. Directions for Use			
8. Name – Prescriber	- Prescriber			
10. Address – Prescriber (Street, City, State, ZIP+4 Code)				
11. Telephone Number – Prescriber				
SECTION III – CLINICAL INFORMATION				
12. Diagnosis – Primary Code and / or Description				
As required in Wis. Admin. Code § DHS 107.10(3)(c), when a prescription is for a BMN drug, the prescriber is required to write "brand medically necessary" in his or her own handwriting. This required statement may be handwritten either directly on the prescription or on a separate order attached to the original prescription. Typed certification, signature stamps, or certification handwritten by someone other than the prescriber does not satisfy this requirement. Blanket authorization for an individual member, drug, or prescriber is not acceptable documentation.				
13. Is "brand medically necessary" handwritten by the prescriber on the prescription or on a separate order attached to the original prescription?				
		Continued		



ECTION III – CLINICAL INFORMATION (Continued)			
4. Has the member experienced an unsatisfactory therapeutic response significant adverse drug reaction with at least two different manufactu generic equivalent drug?		] Yes	□No
If yes, list the manufacturer or National Drug Code (NDC), dates take therapeutic response(s) or clinically significant adverse drug reaction(drugs.		ic details abo	out the unsatisfactory
Manufacturer / NDC	Dates Taken		
Indicate in the space provided the specific details about the unsatisfaction that can be directly attributed to this generic drug.	ctory therapeutic respons	e or clinically	y significant adverse drug
Manufacturer / NDC	Dates Taken		
Indicate in the space provided the specific details about the unsatisfaction that can be directly attributed to this generic drug.	ctory therapeutic respons	e or clinically	y significant adverse drug
Manufacturer / NDC	Dates Taken		
Indicate in the space provided the specific details about the unsatisfacterisation that can be directly attributed to this generic drug.	ctory therapeutic respons	e or clinically	y significant adverse drug
Manufacturer / NDC	Dates Taken		
Indicate in the space provided the specific details about the unsatisfar reaction that can be directly attributed to this generic drug.	ctory therapeutic respons	e or clinically	y significant adverse drug
Note: Pharmacy providers may provide manufacturer or NDC and dat			
<ol> <li>Explain how the BMN drug will prevent the recurrence of the unsatisfadrug reaction described in Element 14.</li> </ol>	actory therapeutic respon	se or clinical	ly significant adverse
6. Has the member taken the requested brand name drug for at least 30 days and had a measurable therapeutic response?	consecutive	Yes	☐ No
If yes, indicate the approximate dates the brand name drug was taken	٦.		
ESTION IV. AUTUODITED SIGNATURE			
ECTION IV – AUTHORIZED SIGNATURE  7. SIGNATURE – Prescriber	18 Г	ate Signed	
	10. L	ato orginod	
ECTION V – ADDITIONAL INFORMATION	L		
9. Additional diagnostic and clinical information explaining the need for t	he drug required may be	included bel	ow.